The Michael Mason prize: development and feasibility testing of a complex intervention to improve adherence to fracture prevention medicine
Authors' conclusion
The multi-facilitated approach to intervention development and testing ensured that the iFraP intervention appears acceptable and feasible for use in UK FLS to support SDM about osteoporosis medicines.
Study context
- Population
- Fracture Liaison Services (FLS) clinicians and patients at one English FLS10 consultations
- Outcome
- Acceptability and feasibility of the iFraP intervention
Methodological detailssingle-centre, theory-based, qualitative interviews, observed and audio-recorded consultations, Development underpinned by theories of shared decision-making (SDM), medicines adherence and behaviour change, seven development studies, and patient and clinician contribution
- Single-centre
- Theory-based
- Qualitative interviews
- Observed and audio-recorded consultations
- Development underpinned by theories of SDM, medicines adherence and behaviour change, seven development studies, and patient and clinician contribution
Main finding
As reported in the abstract
Acceptability and feasibility
- Prototype iFraP delivered in consultations with consenting patients
- 10
Further findings
Intervention development needs
- Patient and clinician unmet needs for personalized, evidence-based information about osteoporosis, its consequences and treatment within and after FLS consultations
Original publication
The Michael Mason prize: development and feasibility testing of a complex intervention to improve adherence to fracture prevention medicine. Rheumatology (Oxford). Published 20 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →